Brevan Howard Capital Management LP Atea Pharmaceuticals, Inc. Transaction History
Brevan Howard Capital Management LP
- $17 Billion
- Q3 2025
A detailed history of Brevan Howard Capital Management LP transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Brevan Howard Capital Management LP holds 29,450 shares of AVIR stock, worth $87,172. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,450
Previous 36,567
19.46%
Holding current value
$87,172
Previous $131,000
35.11%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding AVIR
# of Institutions
123Shares Held
49.3MCall Options Held
54KPut Options Held
98K-
Black Rock Inc. New York, NY9.12MShares$27 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.47MShares$22.1 Million19.85% of portfolio
-
Tang Capital Management LLC San Diego, CA4.83MShares$14.3 Million0.64% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.71MShares$13.9 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.49MShares$7.36 Million2.31% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $246M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...